secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-11-10T13:30:22+00:00
Accession:  0001104659-26-124836
Event type: m_and_a
Sentiment:  positive
Materiality: 0.45
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN; up to $7.1M in payments plus royalties
--------------------------------------------------------------------------------

- Celairis gets exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa, in Australia, New Zealand and ASEAN markets.
- Ocugen receives an upfront fee plus development/milestone payments up to $7.1M, including $6.1M tied to the upfront payment and Phase 3 liMeliGhT top-line data expected in Q1 2027.
- Separate $1.0M milestone payable on Therapeutic Goods Administration approval in Australia; Ocugen also gets a high single-digit percentage royalty on net sales and 50% of gross profits.
- Ocugen retains sole manufacturing rights and the parties target a supply agreement within 90 days; territory covers an estimated 725 million people and can expand by mutual agreement.
- Ocugen calls it the third strategic regional partnership for OCU400; U.S. BLA and EU MAA filings are planned after the Q1 2027 topline readout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/0001104659-26-124836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/tm2629434d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-124836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer